AI-Powered Creator Monetisation Platform, Fanvue, Hits $100m Run Rate and Raises $22m Series A Investment - as Leading Global Creators Rush to Join the Platform
19.1.2026 01:01:00 CET | Business Wire | Press Release
Fanvue, the AI-powered creator monetisation platform with a $100m-plus run rate, has announced a $22m Series A investment round.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112458975/en/
Joel Morris, Will Monange and Harry Fitzgerald (left to right)
Fanvue has bet big on AI-powered tools changing the face of an industry estimated to be worth over $500B by 2030. The platform, which recently crossed $100m annualised revenue, has over 17 million monthly active users, and is home to 250,000 creators who are using Fanvue’s pioneering AI tools to scale their businesses and earn.
Instead of competing with legacy platforms, Fanvue is defining a new category, the Creator AI Economy. Fanvue’s belief is that the next generation of creators will accelerate their earnings through utilising technology. And it’s happening in real time. According to Fanvue, just over 93% of creators on the platform used at least one of the platform’s proprietary AI tools, which include Analytics, Voice and Content.
Investors share Fanvue’s vision for the AI-powered creator economy. The Series A was led by Inner Circle (www.iccap.co), backed by 50+ exited founders, financiers and cultural icons across sport and entertainment, whose portfolio also includes Revolut, Anthropic and xAI. Other notable backers include Moonbug founder René Rechtman, who oversaw its multi-billion-dollar exit, the founders of UK unicorn Marshmallow, and GPs from leading European venture firms.
James Cox, Co-Founder of Inner Circle, commented:
“AI is redefining the creator economy. Fanvue isn’t reacting to that shift; they are pioneering it. Joel, Will, Harry and the team are building the category-defining platform, enabling creators globally to monetise their audiences at scale. We’re proud to be their partner, opening up our community’s access, influence and distribution as they scale.”
Underpinning Fanvue’s AI-powered solutions for the Creator AI Economy are three fundamental values: Fan Connection, Creator Freedom, and Business Ownership. These values stem from the experiences of Co-Founder and former YouTuber, Joel Morris, who identified pain points as a creator that needed fixing - launching Fanvue in 2022 alongside fellow Co-Founders, Will Monange, and Harry Fitzgerald.
The business reported a 450% revenue increase YoY, while their global staff headcount has increased from 42 to 115 in 12 months. The leadership team and the core of the business operate from its London hub in Canary Wharf. Fanvue was recognised as the Fastest Growing Company in Europe at the recent International Business Awards (Stevies).
Fanvue has just announced the signing of Alisha Lehmann, the Swiss pro-footballer, who has become one of the world’s leading content creators, with over 16 million followers on Instagram.
It’s a “huge statement and a stamp of approval for Fanvue’s vision”, says Co-Founder and CEO, Will Monange, who added:
“Announcing two major milestones for the business, the Series A and Alisha, in the same week, reinforces our vision that AI will enable the next generation of athletes and creators to build businesses and create new revenue streams on direct-to-fan monetisation platforms like Fanvue.”
Over 20,000 new creators joined Fanvue last month, with a series of major mainstream creators expected to be announced at the start of 2026.
Fitzgerald, Co-Founder and COO, commented:
“Thanks to AI, creators on Fanvue will be able to scale products, content, and connections in ways that weren’t possible before. The technology will shift creators' ability to directly monetise their fanbases, when traditionally they've had to rely on advertising. We’re building a product that will revolutionise the creator economy.”
The $22m Series A investment will be used to accelerate Fanvue’s global expansion, invest in world-class talent, and leverage AI capabilities to build a product and team that Co-Founder and CEO, Joel Morris, believes will “change the face of the Creator Economy for good”.
Morris added:
“We’ve quietly been building a world-class team from our London base, hiring from Amazon and TikTok in key leadership positions to deliver on our vision to transform how creators monetise content on a global scale. This fundraise enables us to accelerate those plans. We’re just getting started.”
-Ends-
Notes to Editors:
About Fanvue
Fanvue is the fastest-growing subscription platform in the creator economy, with 17 million monthly active users and over 250,000 creators.
Business Awards
- Fastest Growing Company in Europe at the recent International Business Awards (Stevies)
- Sunday Times Best Places to Work 2025, due to its innovative culture and commitment to building a world-class environment for talent
View source version on businesswire.com: https://www.businesswire.com/news/home/20260112458975/en/
Contacts
UK-based reporters can get in touch with gabriella@ideafarmer.co.uk or
scarlett@ideafarmer.co.uk, and US-based reporters can email
mereditheklein@gmail.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press Release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press Release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press Release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press Release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press Release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom